Description
The Air Force Medical Service is conducting market research to identify a portable, battery‑operated cell‑salvage system that can collect, condition, and autonomously return a patient’s own blood in austere, far‑forward environments. The device must operate without donor blood, be shelf‑stable, and meet strict performance criteria (flow rates, heating, runtime, emboli removal, hemolysis limits) while being usable by a single operator with minimal training. Respondents must complete a two‑page RFI response packet detailing how their product meets 23 essential characteristics and five optional preferences. This RFI is for information gathering only; no contract award is tied to the response.
• Required capabilities: real‑time pressure monitoring, selectable flow rates up to 1500 mL/min, heating 450 cc from 2 °C to 37 °C in <20 min, <40 lb weight, <8000 in³ volume, 2‑hour battery runtime (with heating).
• Must use FDA‑cleared consumables and have a clear FDA pathway for the device.
• Optional preferences include man‑portability, MIL‑STD‑810G ruggedization, and integration of invasive blood pressure, SpO₂, and hematocrit monitoring.